Indian pharmaceutical companies rank top30
Here's a quick overview based on my training data: India has a massive pharmaceutical industry, often called the "pharmacy of the world." Top companies include Sun Pharma, Dr. Reddy's, Cipla, Divis Labs, Lupin, Aurobindo, Biocon, Torrent Pharma, Zydus Lifesciences, and Abbott India, among others. Rankings shift based on revenue, market cap, or sales figures.
Searching sources...
Searching the Web
top 30 Indian pharmaceutical companies ranking 2025 2026 by revenue market cap
Reading Web Page
https://www.globaldata.com/companies/top-companies-by-sector…
Searching the Web
top 30 pharmaceutical companies India BSE NSE market cap ranking 2026 complete list
Here is the Top 30 Indian Pharmaceutical Companies ranked by market capitalisation (2025-26 data from BSE/NSE, GlobalData, and Nifty Pharma Index):
Top 30 Indian Pharma Companies by Market Cap (2026)
| Rank | Company | Market Cap (approx.) | HQ | Key Strength |
|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries | ~₹4.43 lakh cr / $44.7B | Mumbai | India's largest pharma; specialty generics, dermatology, oncology; 100+ countries |
| 2 | Divi's Laboratories | ~₹1.82 lakh cr / $21B | Hyderabad | Pure-play API & CRAMS leader; supplies 95+ countries |
| 3 | Torrent Pharmaceuticals | ~₹1.52 lakh cr / $15.1B | Ahmedabad | Chronic branded generics (cardiac, CNS); #1 in Germany & Brazil among Indian cos |
| 4 | Cipla | ~₹1.13 lakh cr / $11.1B | Mumbai | Respiratory, ARV, HIV/oncology access; founded 1935 |
| 5 | Lupin | ~₹1.12 lakh cr / $11.2B | Mumbai | Inhalation, anti-TB APIs, biosimilars; 8th largest in India pharma market |
| 6 | Dr. Reddy's Laboratories | ~₹1.05 lakh cr / $10.5B | Hyderabad | Global generics, biosimilars, vaccines; ROCE ~20% |
| 7 | Mankind Pharma | ~₹85,000-90,000 cr / $12B* | Delhi | Domestic branded formulations; deep Tier 2/3 penetration |
| 8 | Zydus Lifesciences | ~₹98,802 cr / $9.3B | Ahmedabad | Biologics, vaccines, US formulations; semaglutide approvals |
| 9 | Aurobindo Pharma | ~₹69,000 cr / $8.0B | Hyderabad | Generics + API; exports to 150+ countries; oncology & biosimilars pipeline |
| 10 | Alkem Laboratories | ~₹69,000 cr / $6.7B | Mumbai | Anti-infectives, analgesics; strong branded generics |
| 11 | Abbott India | ~₹62,241 cr | Mumbai | MNC subsidiary; women's health, metabolics, diagnostics |
| 12 | Glenmark Pharmaceuticals | ~₹55,105 cr / $6.4B | Mumbai | Dermatology, respiratory, oncology; Ichnos Biosciences spin-off |
| 13 | Biocon | ~₹45,590 cr | Bengaluru | Biologics & biosimilars pioneer; insulin, oncology MAbs |
| 14 | IPCA Laboratories | ~₹33,971 cr | Mumbai | Anti-malarials, cardiovascular, APIs |
| 15 | Piramal Pharma | ~₹25,410 cr | Mumbai | CDMO services, complex injectables, branded generics |
| 16 | J.B. Chemicals & Pharmaceuticals | ~₹22,000-24,000 cr | Mumbai | Cardiac, GI, derma; strong in Russia & South Africa |
| 17 | Natco Pharma | ~₹20,000 cr | Hyderabad | Oncology generics, specialty APIs, US para-IV pipeline |
| 18 | Ajanta Pharma | ~₹18,000-20,000 cr | Mumbai | Branded generics; Africa, Asia, cardio & derma |
| 19 | Sanofi India | ~₹15,000-17,000 cr | Mumbai | MNC subsidiary; diabetes, vaccines, CNS |
| 20 | Pfizer India | ~₹14,000-16,000 cr | Mumbai | MNC subsidiary; hospital injectables, vaccines, oncology |
| 21 | Suven Pharmaceuticals | ~₹13,000-15,000 cr | Hyderabad | Specialty APIs, CRAMS for CNS drugs |
| 22 | Granules India | ~₹10,000-12,000 cr | Hyderabad | Bulk actives, PFIs, finished dosages; paracetamol major |
| 23 | Solara Active Pharma Sciences | ~₹9,000-10,000 cr | Chennai | Standalone API manufacturer |
| 24 | Strides Pharma Science | ~₹8,000-9,000 cr | Bengaluru | Regulated market injectables & softgels |
| 25 | Laurus Labs | ~₹20,000+ cr | Hyderabad | ARV APIs & finished dosages; CDMO oncology |
| 26 | Eris Lifesciences | ~₹8,000-9,000 cr | Ahmedabad | Chronic therapies; diabetes, cardiac, CNS |
| 27 | Sequent Scientific | ~₹5,000-6,000 cr | Mumbai | Animal health / veterinary pharma |
| 28 | Wockhardt | ~₹5,000 cr | Mumbai | Antibiotic R&D (novel antibiotics pipeline), injectables |
| 29 | Cadila Pharmaceuticals (private) | N/A (unlisted) | Ahmedabad | Private; oncology, biologics, veterinary |
| 30 | Venus Remedies / Marksans Pharma | ~₹3,500-4,500 cr | - | Niche formulations, EU/US generic exports |
*Mankind Pharma's GlobalData figure is from Sep 2024 ($12B); more recent BSE data shows₹85,000-90,000 cr. Laurus Labs (₹20,000+ cr) would rank higher than some entries above if using latest data.
Key Highlights
- India is the world's 3rd largest pharma producer by volume and supplies ~20% of global generic medicines.
- Sun Pharma dominates with a ~23% weight in the Nifty Pharma Index and 8.4% domestic prescription share (March 2026).
- FY26 standouts: Sun Pharma revenue ₹58,462 cr (+11.9%); Divi's Labs PAT jumped 65% in Q3 FY26.
- Biosimilars & semaglutide (GLP-1) are the hottest growth areas in 2026 - Zydus, Lupin, Torrent all entered the semaglutide market.
- India pharma market size: ~$68 billion (2025), forecast to reach ~$175 billion by 2034 at ~11% CAGR - per IMARC Group.
This is a shared conversation. Sign in to Orris to start your own chat.